Surprising impact of stromal TIL ’s on immunotherapy efficacy in a real-world lung cancer study

Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancer types and a leading cause of cancer-related mortality [1]. The majority of patients have advanced stage at the time of diagnosis. Systemic treatment has been remarkably changed in the recent years, mainly by the implementation of immune checkpoint inhibitors (ICI), resulting in significant improvement of quality of life and survival [2]. Anti-Programmed Death-(Ligand)1 (anti-PD-(L)1) antibodies are currently part of the treatment for virtually all advanced NSCLC patients without targetable mutations.

Source: Lung Cancer - January 13, 2021 Category: Cancer & Oncology Authors: S. Hashemi, M.F. Fransen, A. Niemeijer, N. ben Taleb, I. Houda, J. Veltman, A. Becker- Commissaris, H. Daniels, L. Crombag, T. Radonic, Jongeneel, S. Tarasevych, E. Looysen, M. van Laren, M. Tiemessen, V. van Diepen, K. Maassen-van den Brink, E. Thunniss Source Type: research